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Abstract: The role of interactions between tumor cells and autologous immunocompetent cells, the impact on the
modulation of the activity of T CD4+ and CD8+ lymphocytes, as well as the influence on the regulation and determina-
tion of antitumor cellular immune response in patients with head and neck squamous cell carcinomas (HNSCC) is not
completely clear. The aim of this study was to analyze early and late activation antigens expression on T cells subpopula-
tions modified under the influence of the presence of cancer cells to investigate the regulatory mechanisms of the local
cellular immune response in carcinoma of the larynx. Cytofluorymetric analysis of the early (CD69+, CD71+) and late
activation markers (CD25+high, CD26
+, HLA/DR+) expression on T CD3+CD4+ and CD3+CD8+ cells subpopulations
in mixed cellular cultures of freshly isolated tumor cells (MLTMC) and non-cancerous normal epithelial cells (MLNCC)
with immunocompetent cells was performed in 55 cases of squamous cell laryngeal carcinoma. The whole peripheral
blood concentrations of IL-10 and IFN-g in 21 h and 72 h of experiments were also measured by ELISA. The relation-
ships between the activation markers expression depending on the type of cells used in co-cultures, as well as the level of
secreted cytokines, were investigated. Our work has revealed a statistically significant dependence of cytofluorymetric
results on the presence of TMC or NCC in mixed cellular cultures. Increased expression of CD69+, CD71+ and CD25+high,
CD26+, HLA/DR+ antigens on T CD3+CD4+ and CD3+CD8+ cells was higher in MLTMC cultures, in comparison with
MLNCC. We demonstrated negative significant relationships of IFN-g and IL-10 secretion with regard to CD4+CD69+,
CD8+CD69+, CD4+CD71+, CD8+CD71+ antigens expression in 21 h of experiments without mitogenic stimulation.
Furthermore, this study revealed negative significant relationships of IFN-g secretion with regard to CD4+HLA/DR+
and CD8+HLA/DR+ as well as between IL-10 concentration and CD4+HLA/DR+ in trials without PHA stimulation.
Our findings have confirmed a key role for tumor cells in determining the function of T cells involved in the immunolog-
ical processes and impact of neoplastic cells on modulating the activity of T CD4+ and CD8+ lymphocytes in laryngeal
carcinoma. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 579–592)
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Introduction
The role of immune cells in the course of neoplastic
disease, including cancers of the head and neck re-
gion, is not completely clear.
Despite the lack of direct evidence that cells of
the immune system can protect against the develop-
ment and progression of cancer, clinical observations
and experimental studies suggest their activity in the
response against tumor cells of different origins. Un-
fortunately, little is known about the pathomecha-
nisms and mutual interactions between tumor cells
and the autologous immune cells i.e. the impact of
neoplastic cells in modulating the function of cells
involved in the immunological processes, the activity
of T CD4+ and CD8+ lymphocytes and the regulation
and determination of antitumor cellular immune re-
sponse in patients with head and neck squamous cell
carcinomas (HNSCC), in particular with carcinoma
of the larynx. Detailed knowledge about the regula-
tory mechanisms influencing the final result of the
immune response to tumor antigens, understanding
of the interactions of cells involved in immunological
processes ´ cancer cells, as well as indications of the
immunological parameters associated with the clini-
cal and morphological features of neoplastic infiltra-
tion, may therefore be important in determining the
invasiveness of tumor lesions, and thus in assessing
the clinical course, choice of optimal treatment and
prognosis in patients with HNSCC. Precise knowledge
of the immune status of a patient with cancer may
also be one of the prognostic factors taken into con-
sideration in selecting an appropriate model of post-
operative care i.e. an indication of the extent of fol-
low-up carried out in terms of postoperative early
detection of cancer recurrence.
During the activation of T cells at their surface,
the activation marker CD (cluster of differentia-
tion) appears. Depending on the duration of acti-
vation response after the stimulus, CD markers can
be divided into early stimulation (CD69+ and
CD71+) and late activation (CD25+, CD26+, HLA/
/DR+) antigens [1].
CD69+ antigen (also called induced activator mol-
ecule, AIM, MLR3) occurs mainly in stimulated
T cells, but also on B lymphocytes and macrophages.
CD69+ marker has the characteristics of pectin and it
is involved in activating signal transduction, leading
to the synthesis of various cytokines, including IL-2
and IFN-g and the receptor for IL-2 (IL-2R) [1, 2].
CD69+ is the earliest marker that is expressed on stim-
ulated immune cells 2–4 hours after TCR/CD3 re-
ceptor stimulation [1, 2]. CD71+ antigen, which oc-
curs in proliferating cells and macrophages, is also
the receptor for transferrin and the iron transporting
protein. It covalently links the chain of the TCR re-
ceptor on T cells and plays a role in signal transduc-
tion pathways. CD25+ antigen is one of three recep-
tors for IL-2 (IL-2R), known as receptor a, occur-
ring in activated T and B lymphocytes and monocytes
[1]. Mitogenic or antigen stimulation of T cell causes
the appearance of CD25+ on the surface of immuno-
competent cells [3]. CD26+ (dipeptidyl peptidase IV)
is a surface protein that exhibits the characteristics of
a protease. It occurs constitutively in various cell types
involved in immunological processes i.e. T cells, B,
and monocytes. CD26+ appears about 48 hours after
activation on T cells. The function of this molecule is
to enhance lymphocyte activation. It stimulates the
activation of T cells depending on CD3 and CD2 an-
tigens, tyrosine phosphorylation of proteins involved
in signal transduction after stimulation of TCR/CD3
receptor. CD26+ marker substrates are proline-con-
taining peptides such as growth factors, chemokines,
neuropeptides, and vasoactive peptides. It also acts
in the phenomenon of apoptosis, playing an impor-
tant role in tumor development [4, 5]. HLA/DR+ an-
tigen is expressed on B cells, macrophages and it oc-
curs during the later stages of T lymphocytes and NK
cells activation. Increased expression of HLA/DR+
appears about 24 hours after stimulation [1].
The aim of this study was to analyze the activation
antigens expression (early activation markers: CD69+,
CD71+ and late activation markers: CD25+high, CD26
+,
HLA/DR+) on T CD3+CD4+ and CD3+CD8+ cells
subpopulations modified under the influence of the
presence of cancer cells to demonstrate the interac-
tions between tumor cells and the autologous cells
of the immune system as well as to investigate the
regulatory mechanisms of the local cellular immune
response in squamous cell carcinoma of the larynx.
Material and methods
Tissue samples, histological classification and morpholog-
ical features. For this study of archival tissue samples, we
used paraffin-embedded tissues of surgically resected spec-
imens from 55 patients (53 men, two women, aged 48–83
years, mean age 58.3 ± 9) treated for squamous cell laryn-
geal carcinoma. The criteria for participation in this study
were as follows: 1. histologically confirmed diagnosis of car-
cinoma planoepitheliale; 2. primary surgical resection with-
out receiving prior immuno-, radio- or chemotherapy;
3. absence of distant metastases. The lesions were assessed
according to the criteria of the International Union Against
Cancer (UICC-TNM 2009) for head and neck carcinomas
within three days of tissue collection [6]. In this study, 25.4%
(14/55) of all tumors were classified as pT2 stage, 38.2%
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(21/55) as pT3, and 36.4% (20/55) as pT4. Nodal stages were
histologically assessed as pN0 in 70.9% (39/55) of cases,
as pN1 in 12.7% (7/55), as pN2 in 7.3% (4/55), and as pN3
in 9.1% (5/55) of cases. Histological differentiation was
estimated as G1 in 7.3% (4/55), as G2 in 80% (44/55) and
G3 in 12.7% (7/55) of cases of laryngeal carcinoma. The
control group consisted of 51 (41 men, ten women, aged
48–84 years, mean age 57.4 ± 5) healthy volunteers. The
criteria for volunteers were a negative history for autoim-
mune diseases, metabolic and other chronic lesions, as well
as lack of immunosuppressive treatment, radio- or che-
motherapy in the past. Blood and tissue samples were col-
lected and tested for all analysis from all 55 patients and
51 healthy volunteers.
Non-cancerous/cancerous epithelium cells isolation. Af-
ter radical laryngectomy, the surgical tissue specimens
were excised aseptically immediately after operation from
at least four tumor sites: two from the tumor centre and
two from the tumor margin and two sites of normal non-
cancerous laryngeal epithelium (as far as possible away
from the tumor) of the same tumor patients. Fragments
of tissue were washed with PBS to remove contaminated
blood and inserted in RPMI 1640 medium (Biomed, Po-
land) supplemented with antibiotics streptomycin/peni-
cillin/gentamycin 1% v/v (Sigma, Aldrich, Germany). The
whole procedure was performed on an ice plateau. Briefly,
tissue specimens were cut with a surgical knife and minced
with a scalpel. This was done in RPMI 1640 medium
(Biomed, Poland) supplemented with antibiotics strep-
tomycin/penicillin/gentamycin 2% v/v (Sigma, Aldrich,
Germany). Fragments of tissues were then washed three
times with Hanks solution (Biomed Lublin, Poland). Next,
the tumor and normal epithelial pieces were digested
overnight (for 18 h) in Nunc Petri-dishes with 0.16 mg/mL
hyaluronidase (Sigma, Aldrich, Germany), 0.55 mg/mL
collagenase (Sigma, Aldrich, Germany) and antibiotics
streptomycin/penicillin/gentamycin 1% v/v (Sigma, Ald-
rich, Germany) at 37°C, 5% CO2 (Cellstar Incubator).
The digested tissues were pressed gently through a 50-μm
(mesh) sieve (Sigma, Aldrich, Germany) with RPMI
1640 medium (Biomed, Poland). Subsequently, the sus-
pension was washed three times with PBS (without Mg2+
and Ca2+) for 20 min at 8°C by centrifugation in a MPW-
-350R centrifuge at 1,800 rpm/500 rcf and poured over by
dyspase solution 2.4 U/mL, incubated for 30 min at 37°C
and resuspended in 1 mL PBS. The concentration of cells
was estimated using a microscope and Bürker’s cham-
ber. To get rid of the apoptotic and necrotic cells, the
columns of a Magnetic Cell Sorting Separator MACS
(Miltenyi Biotec, Germany) and a Dead Cell Removal
Kit was used. Cells were resuspended at a concentration
of 1 × 105 cells/mL in RPMI 1640 medium. The isolated
cells i.e. tumor marginal cells (TMC) and non-cancerous
normal epithelial cells (NCC), were collected immedi-
ately after the procedure.
FACS analysis of early and late activation antigens on
T CD4+ and CD8+ lymphocytes. Our investigations were per-
formed with the approval of the Ethical Committee of the
Medical University of Lodz, Poland and the National Sci-
ence Council, Poland (No RNN/15/03/KN). Blood was col-
lected directly before premedication into pyrogen free He-
parin Li-tubes (final concentration 10 U/mL) and resuspend-
ed at a concentration of 1 × 106 cells/mL in RPMI 1640
medium (Biomed, Poland) supplemented with antibiotics
streptomycin/penicillin/gentamycin 1% v/v (Sigma, Aldrich,
Germany). Next, blood was incubated in 24-well flat-bot-
tomed plates (Nunc Corp., Roskilde, Denmark) in a final
volume of 0.2 mL (per well) and collected after 24 h at 37°C,
5% CO2 (Cellstar Incubator). The experiences with the use
of mitogenic stimulation with 5 μg of PHA (phytohemag-
glutinin) in cultures were also performed. For immun-
ostaining, the following conjugated antibodies were used:
anti-CD4 FITC labeled (clone RPA-T4), anti-CD4 PE (SK3),
anti-CD8 PE (RPA-T8), anti-CD69 APC (L78), anti-CD71
APC (M-A712), anti-CD25 PE (2A3), anti-CD26 PE (L272)
and anti-HLA-DR APC (L243), all provided by BD Pharm-
ingen. 100 ml of blood was mixed and incubated for 30 min.
at room temperature with appropriate quantities of anti-
bodies or isotype controls. Erythrocyte contamination was
eliminated by the addition of lysing solution (BD Bioscience)
into the samples. After a short incubation and rinsing, the
samples were fixed with 1% paraformaldehyde and analyzed
by flow cytometry (FACSCalibur TM, CELLQuestTM soft-
ware; BD Bioscience). The cell analysis and gates were re-
stricted to lymphocytes in dot-plot. The results were ex-
pressed as mean fluorescence intensity (MFI) of the labeled
surface antigens or percent positive CD4+ or CD8+ cells.
ELISA for IL-10 and IFN-g measurement. Blood was col-
lected directly before premedication (blood samples were
collected before tumor samples) into pyrogen free Heparin
Li-tubes (final concentration 10 U/mL). Peripheral blood
mononuclear cells were checked and counted for viability
using the trypan blue staining method. Next, whole blood
was resuspended at a concentration of 1 × 106 cells/mL in
RPMI 1640 medium and incubated in a 96-well plate in
a final volume of 0.1 mL (per well). The supernatants of
cultures were collected after 21 h and 72 h at 37°C, 5% CO2
(Cellstar Incubator). Concentration of IL-10 and IFN-g was
assayed using the immunoenzymatic method ELISA using
Human IL-10 (sensitivity 2 pg/mL) and IFN-g (1 pg/mL)
ELISA SET BD Opt EIA (San Diego, CA, USA). The sam-
ples’ absorbance was read on an ELx808 reader at the wave-
length 450 nm (BioTek Instruments, Winooski, VT, USA). The
experiences with the use of mitogenic stimulation with 5 μg of
PHA (phytohemagglutinin) in cultures were also performed.
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Mixed cellular cultures formation. The experiments in vit-
ro were performed in the following cellular cultures of im-
munocompetent cells of whole blood (L — lymphocytes)
with both freshly isolated tumor cells (TMC) and non-can-
cerous epithelial cells (NCC) (at a ratio 10:1): MLTMC —
mixed autologous lymphocytes and tumor marginal cells;
MLNCC — mixed autologous lymphocytes and non-can-
cerous cells; MLTMCPHA — mixed autologous lymphocytes
and tumor marginal cells with mitogenic stimulation;
MLNCCPHA — mixed autologous lymphocytes and non-can-
cerous cells with mitogenic stimulation.
Statistical analysis of data. None of the parameters record-
ed in material studied passed tests for being normally dis-
tributed (Kolmogorov–Smirnov test), and they were analyzed
with nonparametric analysis of variance by ranks (Kruskal–
–Wallis test, Spearman test) and within group differences by
post hoc analysis with Mann–Whitney U test and Dunnett
correction for multiple comparisons. A value of p £ 0.05 was
considered statistically significant. All data was analyzed us-
ing STATISTICA version 9.0 (StatSoft, Poland).
Results
The activation antigens expression on T CD3+CD4+
and CD3+CD8+ cells subpopulations in the studied
group and the control group. The early activation
antigens (CD69+ and CD71+) and the late activation
markers (CD25+high, CD26
+, HLA/DR+) expression
In the studied group, mean values of CD4+ and
CD8+ activation antigens expression on T cells sub-
populations, measured as a percentage of T cells with
positive expression, were lower compared to the con-
trol group. The mean values were (% ± SEM): 34.6 ±
± 7.16 for CD3+CD4+ and 30.2 ± 5.82 for CD3+CD8+
in patients with laryngeal squamous cell carcinoma,
and 40.6 ± 7.17 for CD3+CD4+ and 31.0 ± 4.75 for
CD3+CD8+ in the control group. We observed signif-
icant differences in CD3+CD4+ activation antigen
expression between these two groups (p = 0.01). CD4+/
/CD8+ ratio in the study group and the control group
was: 1.2 (34.6:30.2) and 1.4 (40.6:31.0), respectively.
Statistically significant differences of white blood cell
count (WBC) in patients with laryngeal carcinoma and
control groups were not noted. WBC ratio in the ana-
lyzed groups was 8.5 ± 2.6 × 103/μL in the study group
and 7.8 ± 3.4 × 103/μL in the control group.
The evaluation of CD69+ and CD71+, the early
activation antigens and CD25+high, CD26
+, HLA/DR+,
the late activation markers expression on CD3+CD4+
and CD3+CD8+ T cells demonstrates the presence of
significant differences between the studied group and
the control group in experiments without mitogenic
stimulation. Patients with laryngeal carcinoma were
characterized by significantly higher values of the av-
erage expression of CD8+CD69+ (p = 0.002),
CD4+CD71+ (p = 0.01) and CD8+CD71+ (p = 0.05).
In addition, our research also confirmed significantly
lower average expression of CD4+CD26+ (p = 0.04)
and CD8+CD26+ (p = 0.02), as well as higher val-
ues of the average expression of CD4+HLA/DR+
(p = 0.05) in the studied group compared to the con-
trol group. Similar relationships concerned the early
and the late activation antigens expression in experi-
ments with mitogenic stimulation. Patients with la-
ryngeal tumors were characterized by significantly low-
er values of the average expression of CD8+CD26+PHA
(p = 0.03) and higher values of the average expression
of CD8+CD26+PHA (p = 0.03) and CD4
+HLA/DR+PHA
(p = 0.02), compared to the control group. The mean
expressions of the early and the late activation mark-
ers and the statistical test results are shown in Table 1.
To check whether the early activation antigens
(CD69+ and CD71+) and the late activation mark-
ers (CD25+high, CD26
+, HLA/DR+) expression on
T CD3+CD4+ and CD3+CD8+ cells subpopulations
can be modified in vitro under the influence of the
presence of cancer cells, mixed cellular cultures were
performed. Our study confirmed the interactions be-
tween tumor cells and the autologous cells of the im-
mune system in the group of laryngeal squamous cell
carcinomas. The mean expressions of the early and
the late activation markers with regard to the cell types
used in mixed cellular cultures (MLTMC and
MLNCC) are shown in Tables 2 and 3.
The activation antigens expression on CD3+CD4+
and CD3+CD8+ T cells subpopulations
in the mixed cellular cultures in experiments
without mitogenic stimulation
Data analysis showed a statistically significant increase
in the average expression of the early activation anti-
gens when isolated epithelial tumor marginal cells
(TMC), as well as normal epithelial cells of the lar-
ynx (NCC), were added to blood in the trials without
stimulation. Increased expression of CD69+ and
CD71+ antigens on T CD3+CD4+ and CD3+CD8+
cells was higher in the experiments with tumor cells
(MLTMC), in comparison with the cultures of non-
-cancerous cells (MLNCC). The following statistical-
ly significant differences between mean values of ex-
pression of early markers on T cells subpopulations
and in the analyzed cell cultures were found: increased
expression of CD4+CD71+ in mixed cellular cultures
MLTMC (p = 0.02) and MLNCC (p = 0.02), as well
as an increase in the expression of CD8+CD71+ in
MLTMC cultures (p = 0.05) and MLNCC (p = 0.01).
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Table 1. Activation antigens expression on CD3+CD4+ and CD3+CD8+ T cells in the studied and the control group
Activation antigens Studied group Control group p Studied group Control group p
% ± SEM % ± SEM % ± SEM % ± SEM
Early antigens Without mitogenic stimulation With mitogenic stimulation
CD4+CD69+ 11.1 ± 1.91 5.4 ± 1.07 NS 32.9 ± 3.6 25.5 ± 5.42 NS
CD8+CD69+ 15.1 ± 2.25 5.7 ± 0.71 0.002 45.4 ± 4.08 28.2 ± 5.22 0.02
CD4+CD71+ 6.4 ± 1.31 2.1 ± 0.55 0.01 27.9 ± 3.64 21.3 ± 5.09 NS
CD8+CD71+ 4.3 ± 0.89 1.6 ± 0.36 0.05 22.8 ± 2.72 18.9 ± 3.96 NS
Late antigens Without mitogenic stimulation With mitogenic stimulation
CD4+CD25+high 10.4 ± 1.4 11.7± 1.98 NS 14.9 ±1.4 14.9 ± 1.98 NS
CD8+CD25+high 9.9 ± 1.14 9.4 ± 3.00 NS 13.0 ± 1.83 10.1 ± 2.82 NS
CD4+CD26+ 0.3 ± 0.05 0.5 ± 0.07 0.04 4.6 ± 0.94 5.8 ± 1.00 NS
CD8+CD26+ 20.8 ± 2.35 30.6 ± 2.72 0.02 26.5 ± 2.54 36.8 ± 3.51 0.03
CD4+HLA/DR+ 25.4 ± 2.17 18.4 ± 1.54 0.05 34.9 ± 2.31 25.6 ± 2.19 0.02
CD8+HLA/DR+ 38.4 ± 2.05 34.9 ± 2.78 NS 45.2 ± 2.35 42.6 ± 2.53 NS
Table 2. Early activation antigens expression on CD3+CD4+ and CD3+CD8+ T cells in mixed cellular cultures
Activation antigens Cellular culture % ± SEM Cellular culture  % ± SEM
Early antigens Without mitogenic stimulation With mitogenic stimulation
CD4+CD69+ L 12.2 ± 2.53 L 25.3 ± 4.61
MLNCC 14.2 ± 3.69 MLNCC 31.0 ± 5.51
MLTMC 14.7 ± 4.57 MLTMC 32.5 ± 6.03
CD8+CD69+ L 18.2 ± 3.69 L 36.8 ± 5.3
MLNCC 20.3 ± 5.02 MLNCC 44.5 ± 6.96
MLTMC 24.6 ± 6.15 MLTMC 44.0 ± 7.13
CD4+CD69+ L 8.4 ± 1.79 L 25.2 ± 5.17
MLNCC 19.2 ± 4.20 MLNCC 32.9 ± 6.78
MLTMC 19.3 ± 4.93 MLTMC 31.7 ± 6.62
CD8+CD69+ L 6.5 ± 1.19 L 21.9 ± 3.48
MLNCC 14.6 ± 4.67 MLNCC 25.9 ± 5.04
MLTMC 16.0 ± 5.14 MLTMC 24.8 ± 5.02
No significant differences between the mean expres-
sion of early activation markers comparing cultures
with isolated epithelial tumor marginal cells and nor-
mal epithelial cells of the larynx (MLTMC vs. MLNCC)
in the experiments without stimulation were noted.
The evaluation of CD25+high, CD26
+, HLA/DR+,
late activation markers expression on CD3+CD4+ and
CD3+CD8+ T cells demonstrates the presence of
a significant increase of values of the average expres-
sion when TMC and NCC cells were added in trials
without mitogenic stimulation. MLNCC mixed cul-
tures were characterized by a significantly higher lev-
el of CD8+CD25+ antigens expression (p = 0.04),
compared to cultures of T CD3+CD8+ cells. Similar
relationships concerned the CD8+CD25+ activation
antigens in experiments with tumor cells MLTMC
(p = 0.03). No significant differences between the
mean expression of the late activation markers com-
paring cultures with isolated epithelial tumor mar-
ginal cells and normal epithelial cells of the larynx
(MLTMC vs. MLNCC) in the trials without stimula-
tion were noted. The mean expressions of the activa-
tion markers with regard to experiments without
mitogenic stimulation and the statistical test results
are shown in Figures 1A and 1B.
The activation antigens expression on
T CD3+CD4+ and CD3+CD8+ cells subpopulations
in the mixed cellular cultures in experiments with
mitogenic stimulation
Our data demonstrates a statistically significant in-
crease in the average expression of the early activa-
tion markers when isolated epithelial tumor margin-
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al cells (TMC), as well as normal epithelial cells of the
larynx (NCC), were added to blood in the experiments
with mitogenic stimulation. Increased expression of
CD25+high and CD26
+ as well as HLA/DR+ antigens
on T CD3+CD4+ and CD3+CD8+ cells was higher in
the mixed cultures with tumor cells (MLTMCPHA),
in comparison with the cultures of non-cancerous cells
(MLNCCPHA). We discovered statistically significant
differences between mean values of CD8+CD71+
antigen expression on CD8+ T cells subpopulation and
in mixed cellular cultures MLTMCPHA (p = 0.02). Our
results also indicated a significant difference between
CD8+CD71+ on CD3+CD8+ T cells and in MLNCCPHA
cultures (p = 0.04). No significant differences between
the mean expression of early activation markers com-
paring cultures with isolated epithelial tumor mar-
ginal cells and normal epithelial cells of the larynx
(MLTMCPHA vs. MLNCCPHA) in the experiments with
stimulation were noted.
In contrast, the evaluation of CD25+high, CD26
+,
HLA/DR+, the late activation markers expression on
T CD3+CD4+ and CD3+CD8+ cells demonstrates no
statistical changes of values of the average expres-
sion when TMC and NCC cells were added in trials
with mitogenic stimulation. Nor were significant dif-
ferences between the mean expression of the late
activation markers comparing cultures with isolated
epithelial tumor marginal cells and normal epithe-
lial cells of the larynx (MLTMCPHA vs. MLNCCPHA)
noted. The mean expressions of the activation mark-
ers with regard to experiments with mitogenic stim-
ulation and the statistical test results are shown in
Figures 2A and 2B.
Table 3. Late activation antigens expression on CD3+CD4+ and CD3+CD8+ T cells in mixed cellular cultures
Activation antigens Cellular culture % ± SEM Cellular culture  % ± SEM
Early antigens Without mitogenic stimulation With mitogenic stimulation
CD4+CD25+high L 11.0 ± 2.29 L 14.4 ± 2.16
MLNCC 9.9 ± 2.79 MLNCC 13.8 ± 3.5
MLTMC 10.9 ± 2.82 MLTMC 12.9 ± 3.48
CD8+CD25+ L 1.7 ± 1.33 L 4.9 ± 1.49
MLNCC 2.0 ± 1.19 MLNCC 5.5 ± 2.35
MLTMC 2.1 ± 1.20 MLTMC 5.1 ± 1.78
CD4+CD26+ L 17.8 ± 3.37 L 22.3 ± 3.96
MLNCC 20.0 ± 5.66 MLNCC 19.5 ± 6.09
MLTMC 22.1 ± 8.3 MLTMC 20.2 ± 7.37
CD8+CD26+ L 5.5 ± 1.74 L 6.2 ± 1.65
MLNCC 4.9 ± 1.61 MLNCC 4.5 ± 1.14
MLTMC 6.2 ± 2.1 MLTMC 5.7 ± 1.34
CD4+HLA/DR+ L 28.3 ± 3.43 L 33.3 ± 5.45
MLNCC 25.4 ± 4.04 MLNCC 33.0 ± 5.06
MLTMC 24.4 ± 4.39 MLTMC 30.8 ± 5.5
CD8+HLA/DR+ L 37.3 ± 3.5 L 42.7 ± 3.56
MLNCC 35.8 ± 4.65 MLNCC 44.7 ± 4.01
MLTMC 39.7 ± 4.07 MLTMC 45.2 ± 3.91
Figure 1. Mean expressions of activation markers and
statistical test results with regard to various types of cells used
in experiments without mitogenic stimulation. (A) Increased
expression of CD4+CD71+ in mixed cellular cultures MLNCC
(*p = 0.02) and MLTMC (**p = 0.02), as well as an increase
in the expression of CD8+CD71+ in MLNCC (***p = 0.01)
and MLTMC cultures (****p = 0.05) were demonstrated.
(B) Increased expression of CD8+CD25+ in MLNCC
(*p = 0.04) and in MLTMC (**p = 0.03) cultures was noted
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Cytokine IL-10 and IFN-g secretion
in the studied group and the control group
We assessed cytokine IL-10 and IFN-g secretion in
whole peripheral blood at two time points (21 h and
72 h of incubation), in trials without and after mitoge-
nic stimulation. The average concentrations of secret-
ed cytokines in the studied group and the control group
were compared. Our results indicated a significant dif-
ference of IFN-g level in 21 h culture with PHA
(p = 0.02) between these two groups. The supernatants
from patients with laryngeal carcinoma were charac-
terized by a significantly lower level of IFN-g, com-
pared to the group of volunteers. No other significant
differences in experiments were noted. However, we
noticed a trend towards IFN-g lower secretion in pa-
tients with laryngeal carcinoma, both in the trials with-
out and with stimulation, as well as towards lower pro-
duction of IL-10 after stimulation. The mean cytokine
concentrations in the studied groups and the statisti-
cal test results are shown in Figures 3A and 3D.
To check whether the early activation antigens (CD69+
and CD71+) and the late activation markers (CD25+high,
CD26+, HLA/DR+) expression on T CD3+CD4+
and CD3+CD8+ cells subpopulations could be asso-
ciated with IL-10 and IFN-g secretion, we rated the
cytofluorymetric assessment against their concentra-
Figure 2. Mean expressions of activation markers and
statistical test results with regard to various types of cells used
in experiments with mitogenic stimulation. (A) Increased
expression of CD8+CD71+ in mixed cellular cultures MLNCC
(*p = 0.02) and MLTMC (**p = 0.04) were demonstrated.
(B) No significant differences in the late activation markers
expression for mixed cellular cultures were disclosed
Figure 3. Mean cytokine production in the studied group and the control group. (A–C) No significant differences in experiments
were noted, although a trend towards IFN-g lower secretion in patients with laryngeal carcinoma, both in the trials without and
with stimulation, as well as a trend towards IL-10 lower production after stimulation, were noticed. (D) A significant difference of
IFN-g level in 21 h culture with mitogenic stimulation (*p = 0.02) between the studied group and the control group was noted
586 K Starska et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0081
www.fhc.viamedica.pl
tions. Our study confirmed the presence of correla-
tions between the analyzed activation markers expres-
sion and the immunoregulatory cytokine level in the
group of laryngeal squamous cell carcinomas.
The relationships between the activation antigens
expression on T CD3+CD4+ and CD3+CD8+
 cells subpopulations and cytokine secretion
Our data demonstrates the presence of negative sig-
nificant relationships of IFN-g secretion with regard
to the early activation antigens expression:
CD4+CD69+, CD8+CD69+, CD4+CD71+,
CD8+CD71+ in 21 h of experiments, as well as
CD4+CD69+ in 72 h of incubation, in trials without
mitogenic stimulation. In subjects with higher early
activation antigens expression on T CD3+CD4+ and
CD3+CD8+ cells subpopulations, lower IFN-g con-
centrations were detected. We also noted a negative
relationship between both CD69+ and CD71+ sta-
tus on T CD3+CD4+ cells and IL-10 concentration
in 21 h of incubation without mitogenic stimulation.
Patients with carcinomas characterized by the high-
est early activation antigens expression on CD4+ sub-
population were found to demonstrate lower IL-10
concentration. Moreover, in all cases of laryngeal
carcinomas studied, the evaluation of cytokine ex-
pression disclosed the presence of significant posi-
tive relationships between CD4+CD69+PHA,
CD8+CD69+PHA, CD4
+CD71+PHA, CD8
+CD71+PHA
early antigens expression and IFN-g secretion in 21 h
of experiments when stimulated with PHA. In pa-
tients with higher early activation antigens expres-
sion on CD3+CD4+PHA and CD3
+CD8+PHA T cells
subpopulations, higher IFN-g concentrations were
noted. In addition, we confirmed significant nega-
tive relationships between CD4+CD69+PHA,
CD8+CD69+PHA, CD4
+CD71+PHA activation markers
and IL-10 concentrations in 21 h of incubation when
stimulated. In contrast, the evaluation of the early
activation markers expression on CD3+CD4+ and
CD3+CD8+ T cells demonstrates the presence of sig-
nificant positive relationships between
CD8+CD69+PHA, CD4
+CD71+PHA, CD8
+CD71+PHA
early antigens expression and IL-10 secretion in 72 h
of trials with mitogenic stimulation. Patients with car-
cinomas with the highest activation markers expres-
sion demonstrated higher IL-10 secretion. The sta-
tistical test results concerning the early activation
antigens relationships with cytokine production are
shown in Table 4.
Our data demonstrates a statistically significant
increase in the average expression of the late activa-
tion markers in the experiments without mitogenic
stimulation. The presence of negative significant re-
lationships of IFN-g secretion with regard to
CD4+HLA/DR+ and CD8+HLA/DR+ in 21 h of ex-
periments and CD8+HLA/DR+ activation markers
expression in 72 h of incubation was noted. Increased
expression of HLA/DR+ antigens on CD3+CD4+ and
CD3+CD8+ T cells correlated with IFN-g lower pro-
duction. We also discovered a statistically significant
Table 4. Statistical test results concerningearly activation antigens’ relationships with IFN-g and IL-10 production
Cytokines Without mitogenic stimulation
t CD4+CD+ CD8+CD69+ CD4+CD71+ CD8+CD71+
IFN-g 21 h r = –0.67 r = –0.41 r = –0.55 r = –0.56
p < 0.001 p = 0.02 p = 0.002 p = 0.001
72 h r = –0.76 r = –0.59 r = –0.23 r = –0.31
p = 0.02 NS NS NS
IL-10 21 h r = –0.42 r = –0.31 r = –0.37 r = –0.34
p = 0.02 NS p = 0.04 NS
72 h r = –0.11 r = –0.21 r = –0.52 r = –0.37
NS NS NS NS
With mitogenic stimulation
IFN-g 21 h r = 0.49 r = 0.51 r = 0.5 r = 0.46
p = 0.006 p = 0.004 p = 0.006 p = 0.01
72 h r = –0.06 r = 0.33 r = 0.4 r = 0.55
NS NS NS NS
IL-10 21 h r = –0.44 r = –0.35 r = –0.36 r = –0.25
p = 0.01 p = 0.05 p = 0.04 NS
72 h r = –0.05 r = –0.7 r = 0.85 r = 0.7
p = 0.89 NS p = 0.004 p = 0.03
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negative correlation between mean values of HLA/
/DR+ antigen expression on CD4+ T cells subpopu-
lation and IL-10 secretion in 21 h of incubation, in
experiments without mitogenic stimulation.
In addition, the evaluation of CD25+high, CD26
+,
HLA/DR+ activation markers expression on
CD3+CD4+ and CD3+CD8+ T cells demonstrates the
presence of statistical changes of values of the aver-
age production of regulatory cytokines, in trials with
PHA stimulation. In all laryngeal carcinomas cases
studied, the evaluation of cytokine expression dis-
closed the presence of significant positive relation-
ships between CD4+CD26+PHA early antigens expres-
sion and IFN-g secretion in 21 h of experiments when
stimulated with PHA. In patients with higher CD26+
activation antigens expression on T CD3+CD4+ cells
subpopulations, higher IFN-g concentrations were
noted. In addition, we confirmed significant negative
relationships between CD4+ CD25+highPHA activation
marker and IFN-g concentrations in 72 h of incuba-
tion when stimulated. Patients with laryngeal carci-
nomas with the highest CD4+ CD25+highPHA activation
markers expression demonstrated lower IFN-g secre-
tion. The statistical test results concerning the late
activation antigens relationships with cytokine pro-
duction are shown in Table 5.
Discussion
In experimental studies in which the epithelial tumor
cells of laryngeal carcinoma, as well as the normal
epithelial cells of the larynx, were added to blood cul-
ture, a significant increase in the expression of early
activation antigens i.e. CD4+CD71+ and CD8+CD71+
as well as the lack of significant differences for late
stimulation markers on T cells, in addition to
CD8+CD25+ was confirmed. Confirmation of higher
expression of the early activation antigens, and a sig-
nificant reduction in the expression of the late activa-
tion markers on T cells in patients with squamous cell
carcinoma of the larynx, compared to the group of
volunteers, may indicate the cellular immune response
fading and the occurrence of dysfunction in regula-
tory immune mechanisms in patients with cancer. The
declining activity of T CD4+ and CD8+ cells and pro-
gressive dysfunction of regulatory mechanisms in la-
ryngeal squamous cell carcinoma is also evidenced
by no significant differences in the expression of the
late activation markers in experimental studies in
which the epithelial tumor cells of laryngeal cancer
were added to blood culture. The results showed that
in the initial phase of immune response associated
with the appearance of tumor antigens, the activity
of T lymphocytes, both CD4+ and CD8+, is intense.
The observed phenomenon may be related to the
mobilization of immune mechanisms which are de-
signed to prepare the cells involved in immunologi-
cal processes for the appropriate antitumor response.
It is linked, among others, with increased expression
of MHC class I and MHC class II molecules, which
remarkably enhance antigen presentation for T cells,
activation of T lymphocytes that recognize an anti-
gen, differentiation of T cells towards cytotoxic lym-
phocytes, and activation of CD8+ lymphocytes and
Table 5. Statistical test results concerning early activation antigens’ relationships with IFN-g and IL-10 production
Cytokines Without mitogenic stimulation
t CD4+CD25+high CD8
+CD25+ CD4+CD26+ CD8+CD26+ CD4+HLA/DR+ CD8+HLA/DR+
IFN-g 21 h r = 0.04 r = 0.05 r = 0.28 r = –0.01 r = –0.55 r = –0.43
NS NS NS NS p = 0.002 p = 0.02
72 h r = 0.4 r = 0.01 r = 0.07 r = –0.48 r = –0.59 r = –0.73
NS NS NS NS NS p = 0.04
IL-10 21 h r = –0.25 r = 0.07 r = –0.03 r = 0.03 r = –0.44 r = –0.34
NS NS NS NS p = 0.01 NS
72 h r = –0.6 r = 0.05 r = –0.09 r = –0.3 r = 0.05 r = –0.21
NS NS NS NS NS NS
Without mitogenic stimulation
IFN-g 21 h r = –0.06 r = –0.29 r = 0.79 r = 0.06 r = 0.16 r = 0.04
NS NS p < 0.001 NS NS NS
72 h r = –0.73 r = –0.34 r = 0.54 r = –0.33 r = 0.64 r = 0.5
p = 0.02 NS NS NS NS NS
IL-10 21 h r = –0.24 r = 0.07 r = 0.01 r = –0.14 r = –0.16 r = –0.29
NS NS NS NS NS NS
72 h r = –0.35 r = 0.36 r = 0.64 r = –0.04 r = 0.16 r = 0.21
NS NS NS NS NS NS
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NK cells, which have the ability to direct inhibition of
tumor cell proliferation and cytolytic activity against
the tumor cells. It is also connected with induction of
cytokines expression that stimulate the activity of Tc
and Th1 lymphocytes, NK cells and interleukins which
inhibit the functions of Th2 cells [3, 7–11]. The ob-
served decrease in the percentage of T lymphocytes,
both CD4+ and CD8+, reduced expression of the late
activation markers, and no significant differences in
expression of activation antigens in most mixed cel-
lular cultures, points to progressive disability and de-
crease in the effectiveness of antitumor immune
mechanisms, increased with longer duration of tumor
cell interactions. Nor can we ignore the role of the
suppressive effects of tumor cells on the functions of
immune cells. This can lead to the phenomenon of
anergy and immunological tolerance in cancer pa-
tients, and it points to the importance of regulatory
CD4+ lymphocytes, demonstrating an immunosup-
pressive effect on effector cells [8–21].
Analysis of the relationships of the early and the
late antigens expression on T CD4+ and CD8+ cells
to the level of cytokines in peripheral blood also sug-
gest complex disorders of regulatory mechanisms of
the immune response. These observations are con-
firmed by the recorded negative correlations between
the measured parameters, which indicate the absence
of increased expression of the activation markers,
despite the increased secretion of IFN-g in the ana-
lyzed cultures and the need to non-specifically stimu-
late the immunocompetent cells, conditioning the
existence of the positive correlations between the
parameters of the cellular immune response. No ef-
fect of IFN-g, which in normal conditions increases
the expression of MHC molecules on the APC cells
and enhances antigen presentation to lymphocytes Th,
increases Tc lymphocytes cytotoxicity as well as in-
duces expression of cytokines such as IL-1, IL-6, TNF,
and thus stimulates the activity of T CD4+ and CD8+
cells, confirms the immunosuppressive role of tumor
cells on T lymphocytes and indicates a defect in the
immune response [3, 7–11].
In the literature, it has been difficult to find publi-
cations in which the expression of activation antigens
on cells involved in immunological processes in squa-
mous cell carcinoma of the larynx have been analyzed
in detail. The results of the analysis of the early and
the late antigens activation in the study group and
the control group, and the findings of experiments
with cultures of isolated tumor cells, do not have their
counterparts in the literature. This is new scientific
information in the field of immunopathology of squa-
mous cell carcinoma of the larynx, which cannot be
directly compared to data obtained by other research-
ers. A few publications have evaluated the expression
of activation markers on the immune system cells in
the group of cancers of the head and neck region.
Most of these, however, concerned the analysis of
tumor infiltrating cells (TIL) and lymphocytes present
in regional lymph nodes and cells of different origin
such as monocytes and dendritic cells, less frequently
cells in the bloodstream. This does not allow direct
comparisons of results obtained in patients with la-
ryngeal cancer [13, 22–29]. In addition, the findings
show large discrepancies in the assessment of the
T cells activity in various types of head and neck can-
cers, and lead to a different conclusion regarding the
expression of activation markers on T lymphocytes
in patients with neoplastic disease [22–29]. This indi-
cates the necessity of an individual approach to the
immunological phenomena observed in a particular
type of cancer, in order to properly interpret the re-
sults. Only a few selected publications, whose authors
have adopted a similar panel of activation markers
on subpopulations of T lymphocytes and similar re-
search methods, were used.
It should be emphasized that the results of the cit-
ed publications were related to heterogeneous groups
of cancers of the head and neck region, which are
characterized by a different biology. This must have
affected the findings obtained by investigators and the
final conclusions.
Despite these limitations, studies on the patho-
genesis and immunopathology of head and neck car-
cinomas clearly indicate the existence of complex dis-
orders in the regulatory mechanisms of immune cel-
lular response as well as the suppression and de-
creased activity of T cells in cancer patients [22–29].
One reason for the ineffectiveness of the mechanisms
of immune cell response to tumor antigens may be
the reduced rate and/or reduction in the number and
activity of T CD4+ lymphocytes, also confirmed in this
study, which has an impact on the function and activ-
ity of T CD8+ cells. CD4+ T cells play a key role in
initiating and sustaining the immune responses direct-
ed against the tumor cells with T CD8+ lymphocytes.
CD4+ T cells are important in preventing anergy of
cytotoxic lymphocytes and are involved in the forma-
tion of memory CD8+ subpopulation, as well as stim-
ulating macrophages and eosinophils present in the
tumor stroma [30, 31]. In light of the role of T CD4+
lymphocytes in the activation of antitumor mecha-
nisms, reducing the activity of this subpopulation of
T cells results in decreased activity and abnormal cy-
totoxic T CD8+ cell function, but also of other cells
involved in immunological processes such as CD56+
NK cells and macrophages, actively involved in the
cellular response [22–29]. Evidence of suppression of
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the immune response and reduction in the cytotoxic
activity of defense mechanisms directed against tumor
antigens, is provided by the diminished expression of
surface molecules (perforins, granzymes, FasL recep-
tors) on CD8+ T cells and CD56+ NK cells confirmed
in studies by other authors [22]. As mentioned earlier
in this discussion, the phenomenon of apoptosis of
T CD4+ and CD8+ cells occurring in cancer patients,
repopulation of lymphocytes from naïve cells as well
as the immune response determined by the activity of
memory cells are the resultant of immune mechanisms
in cancer disease [8, 12, 23, 24, 28]. A detailed assess-
ment of T CD4+ and CD8+ lymphocytes, including
memory cells, naïve cells and Treg lymphocytes, was
not analyzed in the studied group of squamous cell car-
cinoma of the larynx. However, in the context of the
results and to further analyze the findings of experi-
ments and clinical observations, it seems necessary to
give a brief overview of the importance of shifts in
T-cell subtypes, which impact the activity of the exam-
ined populations.
In the literature, researchers have emphasized the
need for diversification of CD4+ subpopulation in
CD4+CD45RO–CD27+ (naďve CD4+ T cells) pheno-
type cells and the memory T cells (CD4+CD45RO+),
to obtain objective conclusions about the activity and
the number of lymphocytes circulating in patients with
cancer [25, 32].
Kuss et al. [25] showed significant reductions in
both studied subsets of CD4+ T lymphocytes, both
CD4 CD4+CD45RO–CD27+ and CD4+CD45RO+ in
patients with cancers of the head and neck. The same
authors, performing research in a different group of
patients, have also shown significant reductions in the
number of CD4+ T cells, while also highlighting the
presence of characteristic shifts in the subtypes of
these cells, i.e. a significant reduction in the number
of CD4+CD45RO–CD27+ and an increase in subpop-
ulations of memory cells in the whole blood of pa-
tients with HNSCC [32]. Also important in determin-
ing the activity and the number of cells involved in
immunological processes is  differentiation of T CD8+
cells subpopulations in the CD8+CD45RO–CD28+
(naïve CD8+ T cells) phenotype, the memory lym-
phocytes (CD8+CD45RO+CD28+) and the effector
cells (CD8+CD28–), the most important subpopula-
tion in the anticancer defense mechanisms.
Tsukishiro et al. [29] showed a decrease of
CD8+CD45RO–CD28+ T cells subpopulation and an
increase in the number of memory cells and the ef-
fector lymphocytes in the peripheral blood of patients
with head and neck cancers. They found, however,
a much higher percentage of apoptotic cells in a sub-
population of CD8+CD28– compared to
CD8+CD45RO–CD28+, which resulted in a reversal
of the ratio of CD8+CD45RO–CD28+/CD8+CD28–.
The observed phenomenon causes that in the phe-
ripheral blood dominate the less mature and active
cells, which are recruited from naïve T cells. In addi-
tion, severe apoptosis and decrease in the percent-
age of CD8+CD28– effector cells, which have the abil-
ity to cancer cells lysis and IFN-g production in re-
sponse to the presence of tumor antigens and exhibit
high expression of granzyme B, explain the tumor pro-
gression. The results presented in a few publications
regarding the evaluation of the expression of activa-
tion markers on T CD4+ and CD8+ cells in carcino-
mas of the head and neck region, show large discrep-
ancies in assessing the activity of immune cells
[22, 33, 34]. Differences in the conclusions reached
may be associated with the aforementioned different
methodologies, but also there have been insufficient
studies in heterogeneous groups of head and neck can-
cers of different origin.
Bose et al. [22] analyzed the expression of CD69+
molecules on isolated peripheral blood T cells in pa-
tients with cancers of the head and neck region and
confirmed the reduced activity of immune cells, as-
sessed in a 96 hour experience, even after stimula-
tion with phytohemagglutinin (PHA). Aarstad et al.
[33] also assessed the presence of selected activation
antigens on T cells circulating in patients with HNSCC
and the relationship of markers with the effective-
ness of anticancer immunological mechanisms. The
researchers did not find significant differences in the
expression of activation markers examined in the
study group and control group. Vidal-Rubino et al.
[34], who evaluated the presence of CD69+ molecules
on T cells in regional lymph nodes with histologically
confirmed lymphonodulitis reactiva, also found no
significant differences in the expression of CD69+
antigen on immunocompetent cells in patients with
head and neck carcinomas, compared to the expres-
sion of this marker in normal structured lymph nodes
in the control group.
In the literature, we found no publications featur-
ing an analysis of the expression of HLA/DR+ on cir-
culating blood cells involved in immunological pro-
cesses in HNSCC cancers. Most of the articles con-
cerned the analysis of the activity of the marker on
cancer cells isolated from tumor or cell lines and as-
sessing correlation of coexpressed HLA/DR+ on both
tumor cells and immune cells, mainly on tumor infil-
trating lymphocytes (TIL) [16, 35–39]. Evaluation of
HLA/DR+ on these cell types was not studied in this
group of squamous cell carcinoma of the larynx, but
the results presented in the literature clearly indicate
the interactions and the effect of tumor cells on the
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expression of HLA/DR+ activation antigens on cells
of the immune system, and thus on the mechanisms
of anticancer activity. Meissner et al. [37] demonstrat-
ed the relationship between the expression of MHC
class II antigens on the tumor cell lines and the activ-
ity of CD4+ T lymphocytes, induced by the presence
of cancer antigens. However, the authors observed
a lack of expression of MHC class II molecules until
at 86% of cell lines, even in experiments after the in-
duction of IFN-g. Chikamatsu et al. [16] confirmed
the relationship of HLA/DR+ expression on CD4+
T cells with increased secretion of IFN-g measured
in mixed cultures of immune cells with autologous
tumor cells. Gomatos et al. [35] analyzed the expres-
sion of HLA/DR+ on TIL and confirmed the expres-
sion of the molecules in 48.6% of laryngeal cancer
cases and also showed no presence of the late activa-
tion marker on lymphocytes in the control group. The
authors also pointed to a relationship of HLA/DR+
antigen expression with Bax+/Bcl– phenotype of both
immune system cells, as well as the laryngeal cancer
cell lines. Dworacki et al. [40] also confirmed the de-
pendence of ability of T CD3+CD8+ lymphocytes to
infiltrate tumor tissues and the activity of CD3+HLA/
/DR+ cells on the coexistence of HLA class I antigens
on laryngeal cancer cells. The authors noted a higher
percentage of CD3+HLA/DR+ TIL lymphocytes in
tumors that express HLA/DR+. Sikorska et al. [41]
also found a correlation between the expression of
HLA/DR+ on the cancer cells and TIL cells
(CD45RO+) and the ability to infiltrate the tumor
front in squamous cell carcinoma of the larynx.
The presented results confirm the importance of
not only MHC class I antigens, but also MHC class II
molecules on tumor cells in the antigens presenta-
tion and activation of CD8+ T cells, as well as the
CD4+ subpopulation, which also plays an important
role in the antitumor response. This is demonstrated
by the studies of genetic and structural changes that
lead to disturbances in expression of MHC class I
molecules and MHC class II antigens on tumor cells
and indicate the relationship of these aberrations with
a reduced activity of effector cells and the phenome-
non of ‘tumor escape’ against the defense mechanisms
of cellular immune response [35–38, 42–45].
In assessing the activity of immune cells, the regu-
latory role of Treg cells with immunosuppressive prop-
erties is also important. Several investigators have con-
firmed the role of these cells in promoting tumor de-
velopment and progression of head and neck region
carcinomas [12–21, 26, 46]. It should be emphasized
that the activity of immune cells is also a result of im-
munological mechanisms regulated by immunosup-
pressive regulatory Treg cells (CD4+CD25+highFoxp3+),
which exhibit inhibitory properties in particular in re-
lation to CD8+ and CD4+. Regulation of immune re-
sponse dependent on the suppressive Treg cells, which
may be more than 30% of the subpopulation of CD4+
T cells, cannot remain without influence on the activ-
ity of T CD4+CD25– and CD8+ cells [12, 18, 46, 47].
In the literature, the results of research on Treg
activity in various cancers of the head and neck re-
gion clearly show an increase in the percentage of
these cells, from 15.2% to as much as 25–30% of
CD4+ cells in patients with HNSCC, compared to
the control group, for which a percentage of this sub-
population was 5–10% [12, 18, 46, 47]. Badoual et
al. [48] analyzed the activity of T cells infiltrating
the tumor stroma and the relationship between sub-
populations of T lymphocytes in cancers of the head
and neck region and showed a significant advantage
of the number of activated T CD4+CD25+ cells over
the regulatory CD4+CD25+highFoxp
3+ lymphocytes
and lymphocytes showing the expression of
CD4+CD69+ phenotype. They also observed a posi-
tive correlation between the occurrence of the num-
ber of CD4+CD25+ and CD4+CD69+ and did not
show such a connection with the regulatory pheno-
type lymphocytes. It should be noted, however, that
the regulatory cells also undergo apoptosis, which
affects their activity, and indirectly their function,
as well as immunological mechanisms involving other
peripheral blood cells active in immune processes
in cancer. Schaefer et al. [18] demonstrated in their
study that Treg cells CD4+CD25+high in patients with
cancers of the head and neck region underwent ap-
optosis to a much greater extent than CD4+CD25–,
which showed a diminished ability to bind V annex-
in. Other authors also showed increased sensitivity
of T regulatory cells to apoptosis, compared to
CD4+CD25– lymphocytes.
The researchers point to the phenomenon of pref-
erential Treg movement to the tumor tissue as one of
the escape mechanisms from programmed death. This
implies that the circuit is dominated by less mature
Treg cells, recruited from naïve CD4+ T cells
(CD4+CD45RO–CD27+) or from active, highly dif-
ferentiated cells that have lost the ability to migrate,
as well as their helper or cytotoxic properties [18, 47].
Most authors have confirmed, however, an increased
number and increased activity of CD4+CD25+high Treg
cells, both in the tumor infiltrating lymphocytes pop-
ulation TIL and circulating blood cells, which to the
greatest extent determines the development, progres-
sion and higher degree of invasiveness of neoplastic
infiltration in patients with tumors of various origins,
including patients with head and neck carcinomas
[12–17, 19–21, 45–47].
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